Do low TB prevalence and lack of BCG Vaccinations Contribute to Emergence Multisystem Inflammatory Syndrome in Children?

Tareef Fadhil Raham
Consultant pediatrician Al-Elwyia Pediatrics Teaching Hospital Baghdad
tareeffadhil@yahoo.com
+9647901584338

Abstract

Background: Emergence of new multisystem inflammatory syndrome in children (MIS-C) is thought to be associated with COVID-19 pandemic. Covid-19 morbidity and mortality variances among countries have been suggested by previous works to be influenced by BCG and previous latent TB infection (which is reflected by TB prevalence) possibly through inducing heterogeneous immunity against SARS-COV2.
Aim: To examine influence of BCG status and TB prevalence on variances among countries which register new multisystem inflammatory syndrome in children (MIS-C).

Methods: We choose all countries which report MIS-C till 23/6/2020, number of cases for each 10 million capita was examined among 3 categories of countries classified according to BCG program status. TB prevalence, MIS-C no. / 10 million (M) population and Covid- 19 deaths/M are taken as markers. Receiver operation characteristic - (ROC) curve, with some relative indicators such as (sensitivity and specificity rates), estimation area of trade - off between sensitivity and specificity, and cutoff points are used with different studied markers for discriminating different three pairs of countries (which have different BCG practices).

Results: MIS-C No/10 M capita in countries never gave BCG vaccination vs countries currently give vaccine shows area under ROC- curve equal to 0.000 with a symbiotic significant of 0.034 and (95% CI interval of 0.000-0.000) also MIS-C No/10 M capita in countries not currently give BCG vaccination (with previous mass vaccination programs) vs countries currently give mass vaccination shows area under ROC- curve equal to 0.094 with a symbiotic significant of 0.027and (95% CI interval of 0.000 -0.280)

Important not significant finding in MIS-C No/10 M capita in countries never gave BCG vaccination vs countries not currently give vaccine shows area under ROC- curve equal to 0.583 with a symbiotic significant of 0.683 and (95% CI interval of 0.074-0.759). Countries not currently give vaccine make discrimination in other pairs

COVID-19 deaths / M capita in countries never gave BCG vaccination vs countries currently give vaccine shows area under ROC- curve equal to 0.083 with a symbiotic informative and reportable value of 0.077 and (95% CI interval of 0.000-0.309 also COVID-19 deaths/ M capita in countries not currently give BCG vaccination vs countries currently giving vaccine shows area under ROC- curve equal to 0.188 with a symbiotic informative reportable value of 0.089 and (95% CI interval of 0.000-0.452).

Important finding is the not significant association in COVID-19 deaths /M capita in countries never gave BCG vaccination vs countries not currently giving vaccine area under

ROC- curve equal to 0.417   with   a symbiotic significant of 0.683 and (95% CI interval of 0.078 - 0.755). Countries not currently giving vaccine make discrimination in third pair of countries in significant association and not in 1st pair.

Regarding TB prevalence marker or discriminator the areas under curve were informative and reportable and too generating with the leftover markers in all 3 pairs signifying inverse relations with covide-19 mortality and MIS-C no. curves.

Conclusion: BCG vaccinations and high TB prevalence are found to be related to decrease MIS-C no. and COVID-19 deaths this might explain variances among countries worldwide. Further studies to confirm this relations and possible relations of Kawasaki disease like illnesses with previous epidemics is recommended. Review of TB programs in relation to management of latent asymptomatic infections and initiate and consolidate BCG programs might be considered urgently.

Key words: Multisystem Inflammatory Syndrome (MIS-C), Covid-19, TB prevalence, BCG

Introduction

On April 2020, reports emerged from the United Kingdom of a presentations in children similar to incomplete Kawasaki disease (KD) or toxic shock syndrome[1,2,3]. In Italy, approximately 10 suspected Kawasaki-like disease cases have been recorded since 1 January 2020, eight of which were reclassified as new Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 infection in children (PIMS-TS)[4] or multisystem inflammatory syndrome in children (MIS-C) or paediatric hyper inflammatory syndrome, or paediatric hyper inflammatory shock[1]. Classical KD with concurrent COVID-19 also have been reported[5]. MIS-C is hyper inflammatory syndrome with multiorgan involvement have some features similar to those of Kawasaki disease and toxic shock syndrome (KDSS)[6].

 (KD) is an acute febrile systemic vasculitis that predominantly occurs in children younger than 5 years of age and the most common acquired heart disease during childhood in most industrialized countries[7] and is the most common primary vasculitis in childhood, with medium and small sized arteries predominantly affected[8]. The annual incidence of KD is highest in Japan, with more than 300 per 100 000 children aged 4 years or younger affected[9], compared with 25 per 100 000 children aged 5 years or younger in North America[10]and is rarely reported in sub-Saharan Africa[11]. Although KD is less common in western   countries [12]   KD shock syndrome (KDSS) a rare form of KD has a higher incidence in these countries [13] (2.60 to 6.95%)[12,14, 15] ,compared with Asian   countries like Taiwan which reported lower incidence rate (1.45%)[16].

KDSS is often associated with myocarditis and requires critical care support during the acute phase of illness KDSS might mimic toxic shock syndrome[12].

 A high level of circulating pro-inflammatory cytokines might contribute to the distributive component of shock. Indeed, KDD has been found associated with high levels of IL-6, , and procalicitonin[13].Patient with MIS-C also high levels of inflammatory markers, including leucocytosis with a predominance of neutrophils, in addition to high levels of C reactive protein, ESR , procalcitonin, and serum interleukin 6[17]. Furthermore   elevation of

inflammatory markers (cytokines) has been previously demonstrated in inflammatory state for multiple conditions[18]including cytokine storms. Cytokine storm denotes a hyperactive immune response characterized by the release of interferons, interleukins, tumor-necrosis factors, chemokines, and several other mediators. These mediators are part of a well-conserved innate immune response necessary for efficient clearance of infectious agents. Cytokine storm implies that the levels of released cytokines are injurious to host cells[19,20]. Cytokine storms can be caused by a number of infectious, especially viral respiratory infections such as H5N1,H1N1 influenze and SARS-CoV2[21,22] Other causative agents include the Epstein-Barr virus, cytomegalovirus[23]. Likewise in KD circumstantial evidence points to an infectious cause[24]. In the past 20 years, viruses of the coronavirus family have been proposed as possibly implicated in the pathogenesis of Kawasaki disease.[25,26]

It is said that case definition of MIS-C is quite broad and overlaps with Kawasaki disease, and other conditions like juvenile rheumatoid arthritis[27]. On the contrary some experts are concerned that current diagnostic criteria may not capture the true scope of the problem.[28]

The severity of inflammation in KD is reflected by inflammatory parameters; thus, laboratory findings are helpful for diagnosing incomplete KD just like MIS-C. A child is considered to have incomplete KD when there are fewer than 4 clinical features in the presence of fever[1]. "Atypical KD" should be used in the presence of an unusual or odd manifestation of KD (e.g., nephritis or central nervous system complication)[29]. Incomplete KD is considered to be a mild form of KD. Nevertheless, such children may have significant coronary artery sequelae as the diagnosis and treatment are often delayed[30].

Differences in Kawasaki shock syndrome and MIS warrants studies investigating underlying immunological mechanisms. Kawasaki disease in its milder form is prevalent in Asian countries. Furthermore, sever form of KDSS, sever covid-19 and MIS-C observed in western countries while milder in Asian and sub-Saharan Africa.

Cardiac manifestations in MIS-C might mimic Kawasaki or Kawasaki shock syndrome and include myocardial dysfunction, pericarditis, valvulitis, or coronary abnormalities other clinical features may overlap. Reactivation of the Bacillus Calmette–Guérin (BCG) injection site has been listed by the American Heart Association as a significant finding among the diagnostic guidelines for KD[31]. Such finding might account to 50%of patients[32,33] . In spite of that no study done before to show BCG effectiveness in KD disease process. BCG reactivation is thought to happen due to suggested cross reactivity of mycobacterial Heat Shock Protein 65 (HSP65) and the human homologue HSP63. Furthermore, cross immune heterogenecity was suggested between BCG and certain viral diseases since BCG induces trained immunity through expressing heterologous antigens of different pathogens which have been developed and tested since 1991 and[34]. The consistent association between BCG vaccination and reduced severity of COVID-19 observed in these and other epidemiological explorations is remarkable[35]. Furthermore, remarkable association between high TB prevalence and COVID -19 mortality was established in a study before through a possible similar mechanism to BCG[36]. Epidemiological studies are lacking regarding role of BCG or latent TB protection effect on

incidence of MIS-C or KD including KDSS. This study is the first in this aspect handling MIS-C incidence in relation to BCG, TB prevalence and COVID-19 deaths. As far as *Mycobacterium bovis* through BCG has heterogeneous effects to various microorganism possibly including SARS- COV2 and due to possible relation of low TB prevalence to high COVID -19 mortality , I put the question of this paper in such way: whether BCG programs and TB prevalence affect MIS-C morbidity? This study might gain its importance because of no study was done about MIS-C in relation to TB prevalence or BCG vaccination. This might open the door to furtherly identify relations with KDSS, KD or other hyper immune serous conditions.

Material and Methods

Data regarding to MIS-C collected till 23/6/2010 in all countries which register MIS. Then COVID -19 deaths/Million registered as it appeared on public data accessed on 2/7/2020 . Countries BCG practices were put in three different groups:
   1-No vaccination at all and no previous BCG
   2-no current vaccination but with previous vaccination program (ceased BCG vaccinations   previously), and
   3- currently giving mass BCG vaccine through national program .
 Total countries were 15, distributed among that groups status as shown in table No. (1). COVID -19 mortality, data TB prevalence data, and population data are obtained from publically published data. BCG data are obtained from publically available WHO data and various references.
   Receiver operation characteristic - (ROC) curve, as well as some relative indicators

such as (sensitivity and specificity rates), and cutoff points are used for discriminating

different three categories of countries (which have different BCG practices).

Discrimination of these categories done through studied markers. All statistical operations

were performed through using the ready-made statistical package SPSS, ver. 22.

Results and Findings:

Table No. (1): MIS-C No./10M, COVID -19 deaths/Million versus BCG practice group of countries

Countries	MIS cases /10M. pop.	Year Stopped mass BCG vaccination	COVID deaths /M.	TB Prevalence
1-No vaccination at all no previous BCG				
Canada	3.179	0/0	228	6
Italy	1.654	0/0	575	7
United State	5.619	0/0	395	3
Mean	3.484	-	399.3	5.3
2-No current vaccination (previous vaccination)				

Austria	**1.110**	**1990**	**78**	**7**
France	**19.15**	**2007**	**457**	**9**
Germany	**0.596**	**1998**	**108**	**7**
Luxembourg	**79.875**	**2005**	**176**	**8**
Spain	**4.705**	**1981**	**607**	**9**
Sweden	**2.971**	**1975**	**532**	**6**
Switzerland	**3.466**	**1987**	**227**	**6**
United kingdom	**5.892**	**2005**	**647**	**8**
Mean	**14.29**	**-**	**354**	**7.5**
3-Currently giving BCG vaccine				
Greece	**0.959**	**Not stopped**	**18**	**5**
Portugal	**0.981**	**Not stopped**	**155**	**24**
Peru	**0.303**	**Not stopped**	**299**	**123**
Russian Federation	**0.891**	**Not stopped**	**66**	**54**
Mean	**0.78**	**-**	**134.5**	**51.5**

MIS-C : Multisystem Inflammatory Syndrome in children

Table 1 shows collected data for the study sample in terms of country No. of cases, BCG status, COVID -19 deaths and TB prevalence.
Group 1 (No vaccination at all no previous BCG) shows highest mean value for COVID-19 deaths/M and lowest of TB prevalence
Group 3 (Currently giving BCG vaccine) show lowest MIS-C no./M and lowest COVID-19 mortality and highest TB prevalence.

Group 2 **No current vaccination (previous vaccination) group shows highest MIS-C and other parameters was in between.**

We present the results of each BCG status pair for the three BCG groups :

Table No. (2) shows estimates area of trade - off between sensitivity and specificity of markers through plotting sensitivity against a complement specificity outcome to examine that trade - off, which is called (ROC) curve, as well as a significant level for testing area under the guideline of fifty percent, with 95% confidence interval of all probable combinations pairs of countries as follows:

1- Pair of countries with no vaccination program at all (x axis) & no current vaccination program but have previous vaccination program (y axis):

The common think in this pair is that both groups had no vaccination programs at this time whether had previous history of vaccinations or not.

2- Pair of countries with never gave BCG vaccination program (x axis) & those with currently giving BCG vaccination (y axis).

3-Pair of countries with currently no vaccination (ceased   vaccination program) (x axis) & currently vaccinated (y axis).

Findings are:

Findings are : MIS-C No/10 M capita in countries never gave BCG vaccination vs countries currently giving vaccine (pair 2) shows area under ROC- curve equal to 0.000 with a symbiotic significant of 0.000 and (95% CI interval of 0.000-0.000) also MIS-C No/10 M capita in countries not currently give BCG vaccination(ceased mass vaccination programs) vs countries currently give mass vaccination (pair 3) shows area under ROC-curve equal to 0.094 with a symbiotic significant of 0.027and (95% CI interval of 0.000 - 0.280)

Important not significant finding in MIS-C No/10 M capita in countries never gave BCG vaccination vs countries not currently giving vaccine (1st pair) shows area under ROC-curve equal to 0.583 with a symbiotic significant of 0.683 and (95% CI interval of 0.074-0.759) countries not currently giving vaccine make discrimination in 2nd pair of countries in significant association and not in 1st pair.

COVID-19 deaths / M capita in countries never giving BCG vaccination vs countries currently giving vaccine (pair 2) shows area under ROC- curve equal to 0.083 with a symbiotic informative and reportable value of 0.077 and (95% CI interval of 0.000-0.309 also COVID-19 deaths M capita in countries not currently giving BCG vaccination vs countries currently giving vaccine(3d pair) shows area under ROC- curve equal to 0.188 with a symbiotic informative reportable value of 0.089 and (95% CI interval of 0.000-0.452)

Important finding is the not significant association in COVID-19 deaths

/M capita in countries never giving BCG vaccination vs countries not currently give vaccine (1st pair) shows area under ROC- curve equal to 0.417 with a symbiotic significant of 0.683 and (95% CI interval of 0.078 - 0.755). Countries not currently giving vaccine make discrimination in third pair of countries in significant association and not in 1st pair.

Regarding TB prevalence marker or discriminator the areas under curve were informative and reportable and too generating with the leftover markers in all pairs and were 0.833 with 59% CI of 0.572-0.755 in pair one and 0.833 with 95% CI interval of 0.5- 0.500 and 0.750 with 95% CI interval of 0.326-1.174 in pairs 2 and 3 respectively. These signifying inverse relations with COVID e-19 mortality and MIS-C no. curves. The informative reportable asymptotic values were0.102,0.157,0.174 for 3 pairs respectively.

Table: (2): Relationships among a diseased groups & controlled for all probable combinations of Disclusion time test in different parameters

Group's Combinations	Parameters	Area	Std. Error	Asymp. Sig.	Asymp. 95% C.I.	
					L.b.	U.b.

I X II	MIS cases /10M pop.	0.583	0.175	0.683	0.241	0.926
	COVID-19 Deaths /M.	0.417	0.173	0.683	0.078	0.755
	TB Prevalence	0.833	0.133	0.102	0.572	1.094
I X III	MIS cases /10M pop.	0.000	0.000	0.034	0.000	0.000
	COVID-19 Deaths /M.	0.083	0.115	0.077	0.000	0.309
	TB Prevalence	0.833	0.170	0.157	0.500	1.167
II X III	MIS cases /10M pop.	0.094	0.095	0.027	0.000	0.280
	COVID -19 Deaths /M.	0.188	0.135	0.089	0.000	0.452
	TB Prevalence	0.750	0.217	0.174	0.326	1.174

[*] **S: Significant at P< 0.05; NS: Non Significant at P> 0.05 ,informative reportable p value>0.05 if close to but does not reach 0.05 and confirmed by minimum confidence interval (Robert J. Nordness, "Epidemiology and Biostatistics Secrets", MOSBY ELSEVIER, 1600 John F. Kennedy Boulevard, Suite 1800 Philadelphia, PA 19103-2899, P156, 2006),I: No vaccinated at all; II: No currently vaccinated; III: Currently giving vaccination.**

Figure (1) represented graphically of ROC Curve plots for studied markers in relative with BCG practices in pair's combinations in light of different three categories conditions.

In order to create a cut-off points for the markers searched between the three pairs of classifiers in relative with BCG practices, and some screening tests such as sensitivity, and specificity rates are presented in table No. (3).

Table: (3): Estimation of sensitivity, specificity rates and construct a cutoff points between different three categories of BCG vaccine due to studied markers

Group's Combinations ((Pairs))	Parameters	Cutoff Points	Sensitivity	Specificity
I X II	MIS cases /10M pop.	3.323	0.625	0.667
	COVID-19 Deaths /M.	591.0	0.250	1.000
	TB Prevalence	7.500	0.500	1.000
I X III	MIS cases /10M pop.	0.597	0.750	0.000
	Covid Deaths /M.	42.000	0.750	0.000
	TB Prevalence	15.50	0.750	1.000
II X III	MIS cases /10M pop.	49.513	0.000	0.875
	COVID -19Deaths /M.	627. 0	0.000	0.875
	TB Prevalence	16.50	0.750	1.000

[*] **S: Significant at P< 0.05; NS: Non Significant at P> 0.05**
I: No vaccinated at all; II: No currently vaccinated; III: Currently giving vaccination.

Results shows that MIS-C cutoff points seems to be inconsistent for the three pairs with too increase for the third pair and lowest in 1st pair.

It is clear that TB prevalence cutoff points are more in 3d pair then 2nd pair both of these pairs have current countries with BCG vaccination   programs.

Discussion

Significant positive relations between   BCG status   with COVID-19 deaths and MIS-C rates   is shown in ROC-Curves. TB prevalence is also significantly associated with similar influence like BCG.

 Regarding MIS-C there is strong relations with BCG status being effective in decreasing incidence in countries currently give BCG vaccine with partial effect on those with previous vaccination programs. Countries never gave BCG vaccine being most severely affected.

Our findings consolidate previous literatures which suggest beneficial effect of BCG in lowering COVID-19[37] mortality. Furthermore, TB prevalence influence on COVID-19 Mortality is also consolidated.

It is obvious that MIS-C was first thought to be KD or KDSS as health authorities in the United Kingdom reported a number of seriously ill children presenting with signs of circulatory shock and hyper inflammatory state, with features consistent of toxic shock or KD in 27 April 2020. Some of the tested children were positive for SARS-CoV-2 infection.

Austria, Greece and Sweden reported not seeing an overall increase in cases of KD. No increase of KD was observed in Asian countries, where KD is much more prevalent than in Europe, such as Japan and South Korea till now. France and Italy observed an unusually high number of children with TSS (with some features reminiscent of KD) in pediatric intensive care; some of those children also tested positive for SARS-COV-2[4]. Even after IMS-C diagnostics criteria have been developed by Royal College of Paediatrics and Child Health (RCPCH) [38] , Centers for Disease Control and Prevention (CDC) [39] and World Health Organization (WHO)[40] there are differences in each criterion, making some believe that these criteria are broad ,[27] others believe these criteria are narrow[28] .

Till 23/6/2020 nine countries reported MIS-C even though many other countries continue to report further. News of confirmed or suspected cases has since emerged from several other countries, including Russia[41], India[42], Pakistan,[43] Iran,[44] Israel[45], and Algeria[46].In Southeast and East Asia, no apparent increase in cases Kawasaki disease was reported[4.]

KD occurred with relatively constant but slowly growing rates. The appearance and subsequent incidence of KD may be associated with the time of industrialization and westernization of these countries[47]. Therefore, it could be postulated that in the past, KD might have appeared in Western countries around the beginning of the 20th century in a form of (infantile polyarteritis nodosa)[48]. Recently, clinical features of KD seem to be changing to milder phenotypes with greater numbers of incomplete KD cases[49].

From the first patient with KD reported in 1961 and the 50 patients published in 1967 by Dr. Tomisaku Kawasaki over the following 5 years[50] KD is thought to be as one of diseases

with excessive immune system response to possibly viral infection [51]. Incidence of KD (per 100,000 less than 5-year-olds) by country[52] in decreasing order of incidence : Japan 308 in 2014[53], South Korea 194.7-217.2 in 2014[54,55] ,China 72.03 in 1.9-116.6 in 2012-2014[50,56], Taiwan 82.8 in 2010[57], Canada 19.6 in 2014[58],United States19.1 in 2015[52], Italy 14.7-17.6in 2013[59,60], Finland in 11.4 in 2009[61], Chile 10.4 in 2011[62], Australia 9.34 in 2009[63], France 9 in 2005-2006, Spain 8 in 2014[64], Inner Mongolia 7.7 in 2013[65], Sweden 7.4 in 2009[61], Germany7.2 in 2012[66], Portugal 6.5 in 2011[67], Netherland 5.8 in 2012[68],united kingdom 4.55 in 2013-2015[69],Thailand 3.43 in 2002[70], Israel 2.03 in 2012[71] . In Latin America the incidence of KD has been reported sporadically in several countries[62,72] . Many nations around the world have demonstrated an increase in the number of children diagnosed with KD since the early to mid-2000s.[73]

In the view of absence of stationary incidence of Kawasaki-like multisystem inflammatory syndrome associated with SARS-CoV-2 infection in Asian countries where the COVID -19 pandemic started, and where the incidence of Kawasaki disease is the highest, is noteworthy[74]. Identifying of factors lead to increase incidence KD in Asia and factors lead to increase of KDSS and KD like illness in Europe and USA should be analyzed in context of recent development of Kawasaki like disease i.e. IMS-C with special consideration to outbakes of KD or KD like illnesses in temporal relations to epidemics and outbakes. Analyses should go retrograde to look for possible epidemiological links to look for evidence of such temporal associations.

In 1918 pandemic no report or for Kawasaki or Kawasaki like syndrome in 1918 pandemic ,but some analyses have shown the virus to be particularly deadly because it triggers a cytokine storm, which ravages the stronger immune system[75].

Since that time literature research on the impact of Spanish influenza does indicate that the Chinese people survived much better than people in the USA and Europe[76]. Even so some patients in China were complicated with bronchitis, pneumonia, and even hemolysis . Erythema was found in some patients were usually misdiagnosed as scarlet fever[76].Rashes might be a very rare flu sign anyhow skin manifestations makes one aware of possible Kawasaki or incomplete Kawasaki in China there before KD disease identified later on . According to Dr. A. Stanley who was employed by the Shanghai Health Bureau at that time in some cases unfortunately these rashes were usually misdiagnosed as scarlet fever[76]. Anyhow rash might be associated with influenza A and typically macular or maculopapular in nature and occurs in about 2% of patients —usually children[77].Furthermore during 2009 pandemic Influenza virus rash is uncommon, and a rare cause of petechial rash in severely affected children were described[78]. According to that the rash associated to Chinese patient more likely is rash of Influenza A as to Dr. A. Stanley said rather than to disease related to Kawasaki or Kawasaki like. The low mortality and morbidity among Chinese people were attributed to Chinese herbals[76].No study done to link between high TB prevalence in China[79] to low mortality from pandemic.

In western countries it looks that the pandemic was sever. To maintain morale, World War I censors minimized reports of pandemic in France (Brest), Germany and the United Kingdom and USA[80].

The major UK troop staging and hospital camp in Étaples in France has been theorized by virologist John Oxford as being at the center of the Spanish flu [81] His study found that in late 1916 the Étaples camp was hit by the onset of a new disease with high mortality that caused symptoms similar to the flu and according to Oxford, a similar outbreak occurred in March 1917 at army barracks in Aldershot[81,82 , 83].Military pathologists later recognized these early outbreaks as the same disease as the 1918 flu[81,84].Furthermore published data from the Austrian archives pointing that the Spanish influenza in Austria began in early 1917[85]. It is of forth mention to say that a disease thought to be measles appeared in 1917–18 produced the highest infection rates in 97 years of continuous military surveillance[86] and extreme case-fatality from aggressive bronchopneumonias and other complications[87]. For reasons that were unclear, infection rates were highest in some camps. Severity statistics were striking: 95 843 measles cases occurred, 22 809 (23·8%) people were admitted to hospital for complications, and 3206 (3.34%) people died. At Camp Pike (Little Rock, AR) they thought that this measles is thought to have killed more soldiers than the 1918 influenza pandemic[87]. These findings make me think that MIS-C like disease might be back to 1917 due to possible relation to H1N1 Spanish flu in mechanisem similar to what happens now with SARS- COV2, specially these bronchopneumonias showed similar streptococcal pathological changes and seem to have been associated with previous respiratory viral infections[88,89]presumably including seasonal influenza and other viruses[87] .Some of these deaths documented not only specific to post measles pneumonias

because an epidemic of severe and fatal primary pneumonia or empyema, or both, in soldiers without measles, which paralleled the measles case-fatality rather than measles incidence[87].

The preeminent pathologist of the camp epidemics, Johns Hopkins' William MacCallum (1874–1944), coined the term interstitial bronchopneumonia to describe 1917 measles (and later, 1918 influenza) autopsy findings[87,90,91].

In recent MIS-C pandemic skin rash is common in more than half reported rash, as the NYC Health Department said[92].

Tuberculosis mortality was in decline in the US since at least the mid-nineteenth century. The overall decline was greatly thought to be accelerated by the 1918 pandemic , but as far as the process would have continued, albeit more slowly, even if the 1918 pandemic had not occurred[93] make me think that the decrease in TB is possibly related to high mortality and complication due to Spanish flue rather than opposite explanation although this should be documented .Here in this paper we show that both TB prevalence and BCG status have influence on both COVID-19 mortality and MIS-C incidence. Is TB through latent or previous infection or through BCG vaccination has cross immunity protection against COVID-19 pandemic and other influenza pandemics making these pandemics more sever in western countries and such severity affect adults and children. Is it probable that when TB prevalence starts to decrease in Asia some sort of hyper immune condition emerges in susceptible children and this took the form of KD or incomplete Kawasaki??

 In Japan large-scale influenza epidemics have occurred in the past, including the Spanish flu during 1918–1920, Asian flu during 1957–1958, Hong Kong flu during 1968–1969, and 2009 H1N1 pandemic during 2009–2010.

Japan started giving mass BCG vaccinations since 1948 till now as national policy, boosters were given also before 2003 and have previous TB programs. The Ministry of Health and Welfare in Japan conducted the first National Tuberculosis Survey in 1953, and found more severe endemic status than expected. In order to improve this situation, "Guidelines for Strengthening of Tuberculosis Control Measures" were issued in 1954. Furthermore by the 1950s developments in medical science for TB treatment, particularly the development of the first effective antimicrobial drugs against TB (i.e., streptomycin, para-amino salicylic acid, and isoniazid), had a big impact on TB control in Japan and other countries [94,95].

 For that reasons TB was transformed from a fatal to a curable disease and by 1961 the mortality rate from TB dropped sharply [94].

Up to my knowledge there is no study done to answer the question of relation of sudden drop of TB prevalence to emergence of Kawasaki disease in Japan or to study the low rate of KDSS in Asia compared to Europe which most of its countries have low TB prevalence and various BCG program practices. Experts are looking for increase in KD in Asian countries at the current time, but this might need time to be obvious according to history of previous epidemics and outbakes.

In japan the major peak in influenza cases in 1957 represents the country's first exposure to the H2N2 subtype, which caused the 1957 Asian flu pandemic which is a new influenza A (H2N2) virus emerged in East Asia, triggering a pandemic. The quite extensive outbreaks in 1962 and 1965 were due to H2N2 variants that arose from antigenic drift[96].

13 outbreaks of swine influenza were recognized in Japan from 1978 to 1979. Thirty-seven influenza viruses were isolated from nasal swabs of diseased pigs in 13 outbreaks. During the winter of 1978–79, the reappearance of the A(H1N1) virus coincided in some countries with epidemics of A(H3N2), and several instances of co-infection were reported in the United States and Japan[97].

Furthermore influenza type B viruses were associated with increased morbidity widespread illness in schoolchildren in Japan in February 1982 [98] were associated with increased morbidity in some regions of the Union of Soviet Socialist Republics (USSR) in November and December 1981.

The 1986-87 influenza epidemic was caused by influenza A(H1N1) viruses resembling A/Taiwan/1/86(H1N1), a variant first isolated in China, Malaysia, Japan, and Singapore during January-April 1986[99] . Shortly after and on word and possibly temporarily associated with 4 previous out brakes of 1962 and 1965,1978-1979,1982, 1986, three large KD epidemics were recorded in Japan—in 1979, 1982, and 1986 in addition to the first reported by Tomisaku Kawasaki in January 1961, and his later report on 50 similar cases in 1967 [50] just one year before 1968 flu pandemic.

The reported annual incidence rates of KD in Japan were 206.2 and 239.6 per 100,000 children aged 0 to 4 years in 2009 and 2010, respectively; the 2010 rate was the highest ever reported before. In 2009,a new influenza strain (H1N1) was prevalent worldwide, including Japan[100].The influenza epidemic might have changed the epidemic pattern of KD. The influenza epidemic might have had an effect as suggested by Yosikazu Nakamura , Mayumi Yashiro, Ritei Uehara,*etal*[100].The temporal associations of KD out brakes in Japan from 60s of last century till 2009 with concurrent virus out brakes is of great concern and the time is too early for japan to say there is no association with current pandemic.

In USA a community-wide outbreak of Kawasaki syndrome, apparently the first in the United States, occurred in Hawaii in the first half of 1978. According to CDC there were isolates of H1N1 in 50 states in 1977 after reports cases in Asia and previous Soviet Union furthermore new variant of H1N1 reported in few states including Hawaii [101].This temporal relation may be related to possible causative virus. Between August 22, 1984, and January 6, 1985, 10 outbreaks of Kawasaki syndrome (KS) Outbreaks occurred in 10 states and the District of Columbia during the 21-week period. Cases from a number of these outbreaks continue to be reported to CDC[102] no research data were found to relate KD out brakes to outbreaks of type A(H1N1) strains during the 1983-1984 influenza season[103] but the temporal association is evident.

In South Korea the incidence rates of KD just after 2009 influenza pandemic in children younger than 5 years increased from 115.4 per 100,000 children in 2009 to 134.4 per

100,000 children in 2011[55,54]. The incidence furtherly increased   to   170.9, 194.9 and 194.7 in 2012, 2013 and 2014, respectively[55].TB prevalence in south Korea was 80 /100000 in 2011 decreased to 66 in 2018[104]. Compared to Japan South Korea have lesser incidence of KD and higher TB prevalence since South Korea start BCG at late times in 70s and stopping boosters in 2007[105].

In China: the start and peak of Kawasaki epidemics are in 1979, 1982, and 1986, these out brakes are coincidental to Japan's for mentioned peaks of KD , furthermore there are seasonal outbreaks between 1987-2010 [106]. In general, KD incidence is low in China compared to Japan with trends to increase in recent years. The mean incidence in Sichuan Province (2003-2007)   was documented to be 7.1 per 100,000 children <5 years[107]. Data from Hong Kong also showed an increase in incidence from 26 in 1994 to 39 in 2000 and to 74 per 100,000 in 2011[108].

The "flu" of 1979 originated in fact in mainland China in early 1977 which was caused by another "new" virus that is not new at all but which circulated widely in the early 1950's, then vanished with the advent of "Asian" (H2N2) influenza in 1957[109]. Furthermore, Influenza A(H1N1) virus was isolated in China in 1982. According to CDC virus of this subtype has not previously been isolated [110]. Furthermore, a new variant of H1N1 was isolated for first time in China as mentioned before during early months in   1986. The KD out brakes look to be temporally associated with these influenzas out brakes.   Although the prevalence of TB changed little from 134.27 in 1990 to 137.93 in 2015 per 100,000 persons[79]. TB prevalence again is higher than Japan which might explain lower incidence of KD in China compared to Japan. This further association with declining of TB prevalence is of further concern.

In Europe, the epidemiology of KD ranges from 3.6 to 15.2/100,000[60] but (KDSS) has a higher incidence in these countries[13], compared with Asian countries, the real cause for high incidence of KDSS in western countries is   unknown yet. Low TB prevalence and lack of BCG vaccination might make these countries reporting higher rates of KDSS.

BCG unlike natural infection gives protection to 50%-60 %[111] of target population. This might possibly have explained emergence of KD when TB prevalence start to decrease in communities to relatively medium level of TB prevalence. In contrast higher rate of KDSS are found in unvaccinated communities and lower TB prevalence although KD is lower than Asian countries. We found here in this paper higher incidence of IMS-C associated with low TB prevalence countries and associated with lack of BCG programs. The incidence of IMS-C varies within European countries possibly due to variations in   BCG recommendations. BCG practices differ in Europe as follows:[112] there are 12 countries do not include BCG in their normal vaccination schedules (Austria, Belgium, the Czech Republic, Denmark, Germany, Iceland, Italy (start 1970 and stopped 2001) Liechtenstein, Luxembourg (stopped mass vaccination previously BCG coverage was 20% on 2005 and 60% on 1995- 1998[113]), the Netherlands, Slovakia, and Spain); there are 11 recommend its use in all newborns at the time of birth (Bulgaria, Croatia, Estonia, Greece, Hungary, Ireland, Latvia, Lithuania, Poland ,Portugal, and Romania), The remaining 8 (Cyprus, Finland, France stopped mass vaccination on 2004), Malta, Norway, Slovenia, Sweden,

and the United Kingdom) recommend it only for certain categories of children considered at risk, mainly the children of parents coming from TB endemic countries and those with a case of TB in their families[112].

Conclusions: This study shows a strong relation between BCG and MIS-C, between BCG and COVID – 19 deaths, between TB prevalence and MIS-C and between TB prevalence and COVID-19 deaths.

Recommendations:

My recommendations are that:

1- clinical trials are required to confirm established epidemiological relations.

2- to review TB programs and might consider revaccinate people with primary BCG vaccinations and further booster doses.

3- review previous epidemics and find correlations with KD or KDSS or other related conditions.

There is no conflict of interest.

There is no funding received.

Acknowledgment:
I am deeply grateful to Emeritus Professor Abdulkhaleq Abduljabbar Ali Ghalib Al-Naqeeb, Ph.D. in the Philosophy of Statistical Sciences at the Medical & Health Technology college, Baghdad-Iraq, for his assistance and supported in data analysis, interpretations of finding results, and revise and display the paper.

[1] Son, MBF , Friedman,K .Coronavirus disease 2019 (COVID-19): Multisystem inflammatory syndrome in children. *UPTODATE*.

https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-multisystem-inflammatory-syndrome-in-children?sectionName=CASE%20DEFINITION&topicRef=2841&anchor=H1928154455&source=see_link

Accessed on 15/7/2020

[2] Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. *Lancet*. 2020;395(10237):1607-1608. doi:10.1016/S0140-6736(20)31094-1

[3] PICS ,2020Paediatric *Intensive Care Society (PICS) Statement: Increased number of reported cases of novel presentation of multi system inflammatory disease.* news
https://picsociety.uk/wp-content/uploads/2020/04/PICS-statement-re-novel-KD-C19-presentation-v2-27042020.pdf
Accessed on July 15, 2020
[4] European Centre for Disease Prevention and Control Pediatric. Rapid risk assessment: paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children. May 2020
Retrieved on 16/7/202 (https://www.ecdc.europa.eu/en/publications-data/paediatric-inflammatory-multisystem-syndrome-and-sars-cov-2-rapid-risk-assessment. opens in new tab).
[5] Jones VG, Mills M, Suarez D, et al. COVID-19 and Kawasaki Disease: Novel Virus and Novel Case. *Hosp Pediatr*. 2020;10(6):537-540. doi:10.1542/hpeds.2020-0123
[6] WHO. *Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19 . Scientific Brief.* News room ,detail .15 May 2020

https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19

. Accessed : 15/7/2020

[7] Wood LE, Tulloh RM. Kawasaki disease in children. *Heart*. 2009;95(10):787-792. doi:10.1136/hrt.2008.143669

[8] Anja S, Christian M H. Childhood Vasculitis . Frontiers in Pediatrics .2019;6

[9] Makino N, Nakamura Y, Yashiro M, *et al*. Nationwide epidemiologic survey of Kawasaki disease in Japan, 2015-2016. *Pediatr Int*.2019;61:397-403. doi:10.1111/ped.13809. pmid:30786118

10 Son MBF, Newburger JW. Kawasaki Disease. *Pediatr Rev*. 2018 Feb. 39 (2):78-90. [Medline].

[11] Noorani M, Lakhani N. Kawasaki disease: two case reports from the Aga Khan Hospital, Dar es Salaam-

[12] Kanegaye JT, Wilder MS, Molkara D, *et al*. Recognition of a Kawasaki disease shock syndrome. *Pediatrics*.2009;123:e783-9. doi:10.1542/peds.2008-1871. pmid:19403470

[13] Li Y, Zheng Q, Zou L, *et al*. Kawasaki disease shock syndrome: clinical characteristics and possible use of IL-6, IL-10 and IFN-γ as biomarkers for early recognition. *Pediatr Rheumatol Online J*. 2019;17:1. doi:10.1186/s12969-018-0303-4. pmid:30611297

[14] Dominguez SR, Friedman K, Seewald R, *etal*. Kawasaki disease in a pediatric intensive care unit: a case-control study. *Pediatrics*. 2008;122(4):e786–e790.

[15] Gamez-Gonzalez LB, Murata C, Munoz-Ramirez M, Yamazaki-Nakashimada M. Clinical manifestations associated with Kawasaki disease shock syndrome in Mexican children. *Eur J Pediatr*. 2013;172(3):337–342.

[16] Lin MT, Fu CM, Huang SK, Huang SC, Wu MH. Population-based study of Kawasaki disease shock syndrome in Taiwan. *Pediatr Infect Dis J. 2013 Dec; 32(12):1384-6.*

[17] Julie Toubiana , Clément Poirault, Alice Corsia, *etal*. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study
BMJ 2020; 369 doi: https://doi.org/10.1136/bmj.m2094 (Published 03 June 2020)

[18] Toshio Tanaka, Masashi Narazaki,and Tadamitsu Kishimoto. IL-6 in Inflammation, Immunity, and Disease. *Cold Spring Harb Perspect Biol*. 2014 ; 6(10): a016295.

[19] Is a "Cytokine Storm" Relevant to COVID-19? Sinha P, Matthay MA, Calfee CS .*JAMA Intern Med.* Published online June 30, 2020. doi:10.1001/jamainternmed.2020.3313

[20] Farsalinos K, Barbouni A, Niaura R. Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option? [published online ahead of print, 2020 May 9]. *Intern Emerg Med*. 2020;1-8. doi:10.1007/s11739-020-02355-7

[21] Wong JP, Viswanathan S, Wang M, Sun LQ, Clark GC, D'Elia RV. Current and future developments in the treatment of virus-induced hypercytokinemia. *Future Med Chem*. 2017;9(2):169-178. doi:10.4155/fmc-2016-0181

[22] Liu Q, Zhou YH, Yang ZQ. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cellular & Molecular Immunology. 2016 Jan;13(1):3-10. DOI: 10.1038/cmi.2015.74.

[23] Tisoncik JR, Korth MJ, Simmons CP, *et al*. Into the eye of the cytokine storm. Microbiology and Molecular Biology Reviews : MMBR. 2012 Mar;76(1):16-32. DOI: 10.1128/mmbr.05015-11.

[24] Nakamura Y, Yashiro M, Uehara R, Oki I, Watanabe M, Yanagawa H. Monthly observation of the number of patients with Kawasaki disease and its incidence rates in Japan: chronological and geographical observation from nationwide surveys. *J Epidemiol*. 2008;18(6):273-279. doi:10.2188/jea.je2008030

25 Esper F, Shapiro ED, Weibel C, Ferguson D, Landry ML, Kahn JS. Association between a novel human coronavirus and Kawasaki disease. *J Infect Dis*. 2005;191(4):499-502. doi:10.1086/428291

26 Turnier JL, Anderson MS, Heizer HR, Jone PN, Glodé MP, Dominguez SR. Concurrent Respiratory Viruses and Kawasaki Disease. *Pediatrics*. 2015;136(3):e609-e614. doi:10.1542/peds.2015-0950

[27] Rowley AH. Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children [published online ahead of print, 2020 Jun 16]. *Nat Rev Immunol*. 2020;1-2. doi:10.1038/s41577-020-0367-5

[28] Phillips D. Diagnostic Criteria May Miss Some MIS-C Cases, Experts Say. Medscape.

https://www.medscape.com/viewarticle/933303?nlid=136249_5141&src=WNL_mdplsfeat_200707_mscpedit_peds&uac=114663BT&spon=9&impID=2450715&faf=1

Accessed: July 02, 2020

[29] Thapa R, Chakrabartty S. Atypical Kawasaki disease with remarkable paucity of signs and symptoms. *Rheumatol Int*. 2009;29(9):1095–6.

[30] Ha KS, Jang G, Lee J, *et al*. Incomplete clinical manifestation as a risk factor for coronary artery abnormalities in Kawasaki disease: a meta-analysis. *Eur J Pediatr*. 2013;172(3):343-349. doi:10.1007/s00431-012-1891-5

[31] Newburger JW, Takahashi M, Gerber MA, *etal*. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.

Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young., American Heart Association., American Academy of Pediatrics.
Circulation. 2004; 110(17):2747-71.

[32] Rezai MS, Shahmohammadi *S*. Erythema at BCG Inoculation Site in Kawasaki Disease Patients.
Mater Sociomed. 2014 Aug; 26(4):256-60.

[33] Uehara R, Igarashi H, Yashiro M, Nakamura Y, Yanagawa H. Kawasaki disease patients with redness or crust formation at the Bacille Calmette-Guérin inoculation site. *Pediatr Infect Dis J*. 2010;29(5):430-433. doi:10.1097/INF.0b013e3181cacede

[34] Camila C, Ayleen F F, Angello RD, *et al*. BCG-induced cross-protection and development of trained Immunity: implication for vaccine design. *Frontiers Immunology*. 2019;   10   :2806. doi:10.3389/fimmu.2019.02806

[35] BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Luis E. Escobar, Alvaro Molina-Cruz, Carolina Barillas-Mury

Proceedings of the National Academy of Sciences. Jul 2020, 202008410; DOI: 10.1073/pnas.2008410117

[36] TF,Raham. TB Prevalence Influence on Covid-19 Mortality. *International Journal of Psychosocial Rehabilitation*. 24(10) ;2020 : 3679- 3690

[37] Soliman R, Brassey J , Plüddemann A, *etal*. Does BCG vaccination protect against acute respiratory infections and COVID-19 ?.A rapid review of current evidence . CEBM . 24/4/ 2020. https://www.cebm.net/covid-19/does-bcg-vaccination-protect-against-acute-respiratory-infections-and-covid-19-a-rapid-review-of-current-evidence. Accessed on 1/7/2020

[38] The Royal College of Paediatrics and Child Health. *Guidance - Paediatric multisystem inflammatory syndrome temporally associated with COVID-19* (PDF)
https://www.rcpch.ac.uk/resources/guidance-paediatric-multisystem-inflammatory-syndrome-temporally-associated-covid-19-pims
Accessed : 18/7/2020

[39] CDC. *Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19)* . emergency.cdc.gov. 19 May 2020.
Accessed 14 july 2020.

[40] World Health Organization. *Multisystem inflammatory syndrome in children and adolescents with COVID-19. Scientific brief*.

https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19
 Accessed on 16 July 2020.

[41] Семенова, Мария (17 June 2020). "В Москве умер первый ребенок из-за новой болезни, вызванной COVID-19" (in Russian). *RIA Novosti*. Retrieved 16 july 2020.

[42] Smith B. Indiana Has First Case of Children's Inflammatory Syndrome Linked to COVID-19 . *Lake Shore Public Radio*. May 18 ,2020

https://www.lakeshorepublicradio.org/post/indiana-has-first-case-childrens-inflammatory-syndrome-linked-covid-19#stream/0

[43] Umer D, Ahmed T .Post-coronavirus Kawasaki-like inflammatory syndrome reported in eight children in Lahore. *Samaa TV*. (8 July 2020). Accessed : 9 July 2020

[44] Bahrami A, Vafapour M, Moazzami B, Rezaei N. Hyperinflammatory shock related to COVID-19 in a patient presenting with multisystem inflammatory syndrome in children: First case from Iran [published online ahead of print, 2020 Jul 8]. *J Paediatr Child Health*. 2020;10.1111/jpc.15048. doi:10.1111/jpc.15048

45 Jaffe- Hofmfman M.What is the new inflammatory syndrome infecting children after COVID-19? Jerusalem *Post*. May 17, 2020

[46] Saada H. "Algeria registers first case of Kawasaki disease". *DZ Breaking* retrieved on 18/7/202

[47] Lee KY, Han JW, Lee JS Kawasaki disease may be a hyperimmune reaction of genetically susceptible children to variants of normal environmental flora. *Med Hypotheses*. 2007; 69(3):642-51.

[48] Lee KY, Rhim JW, Kang JH. Kawasaki disease: laboratory findings and an immunopathogenesis on the premise of a "protein homeostasis system". *Yonsei Med J*. 2012;53(2):262-275. doi:10.3349/ymj.2012.53.2.262

[49] Kim SH, Kim KH, Kim DS. Clinical characteristics of Kawasaki disease according to age at diagnosis. *Indian Pediatr*. 2009;46(7):585-590.

[50] Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. *Arerugi*. 1967; 16:178–222.

[51] McCrindle BW, Rowley AH, Newburger JW, *etal* . Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. *Circulation*. (2017). 135 (17): e927–e999.

[52] Kim G B. Reality of Kawasaki disease epidemiology. *Korean J Pediatr*. 2019 Aug; 62(8): 292–296.Published online 2019 Jul 9. doi: 10.3345/kjp.2019.00157.

[53] Makino N, Nakamura Y, Yashiro M, *et al*. Epidemiological observations of Kawasaki disease in Japan, 2013-2014. *Pediatr Int*. 2018;60(6):581-587. doi:10.1111/ped.13544

[54] Ha S, Seo GH, Kim KY, Kim DS. Epidemiologic Study on Kawasaki Disease in Korea, 2007-2014: Based on Health Insurance Review & Assessment Service Claims. *J Korean Med Sci*. 2016;31(9):1445-1449. doi:10.3346/jkms.2016.31.9.1445

[55] Kim GB, Park S, Eun LY, *et al*. Epidemiology and Clinical Features of Kawasaki Disease in South Korea, 2012-2014. *Pediatr Infect Dis J*. 2017;36(5):482-485. doi:10.1097/INF.0000000000001474

[56] Chen JJ, Ma XJ, Liu F, *et al*. Epidemiologic Features of Kawasaki Disease in Shanghai From 2008 Through 2012. *Pediatr Infect Dis J*. 2016;35(1):7-12. doi:10.1097/INF.0000000000000914

[57] Lin MC, Lai MS, Jan SL, Fu YC. Epidemiologic features of Kawasaki disease in acute stages in Taiwan, 1997-2010: effect of different case definitions in claims data analysis. *J Chin Med Assoc*. 2015;78(2):121-126. doi:10.1016/j.jcma.2014.03.009

[58] Manlhiot C, O'Shea S, Bernknopf B, *et al*. Epidemiology of Kawasaki Disease in Canada 2004 to 2014: Comparison of Surveillance Using Administrative Data vs Periodic Medical Record Review. *Can J Cardiol*. 2018;34(3):303-309. doi:10.1016/j.cjca.2017.12.009

[59] Cimaz R, Fanti E, Mauro A, Voller F, Rusconi F. Epidemiology of Kawasaki disease in Italy: surveillance from national hospitalization records. *Eur J Pediatr*. 2017;176:1061–5.

[60] Mauro A, Fabi M, Da Frè M, *et al*. Kawasaki disease: an epidemiological study in central Italy. *Pediatr Rheumatol Online J*. 2016;14:22

[61] Salo E, Griffiths EP, Farstad T, Schiller B, Nakamura Y, Yashiro M, *et al*. Incidence of Kawasaki disease in northern European countries. Pediatr Int. 2012;54:770–2

[62] Hoyos-Bachiloglu R, García Á, Morales PS, Cerda J, Talesnik E, Borzutzky A. Geographic distribution of Kawasaki disease throughout Chile. Rev *Chilena Infectol*. 2016; 33:12–8

[63] Saundankar J, Yim D, Itotoh B, Payne R, *et al*. The epidemiology and clinical features of Kawasaki disease in Australia. *Pediatrics*. 2014;133:e1009–14

[64] Sánchez-Manubens J, Antón J, Bou R, Iglesias E, *et al*. Kawasaki Disease in Catalonia Working Group Incidence, epidemiology and clinical features of Kawasaki disease in Catalonia, Spain. *Clin Exp Rheumatol*. 2016;34(3 Suppl 97):S139–44.

[65] Zhang X, Liang Y, Feng W, *et al*. Epidemiologic survey of Kawasaki disease in Inner Mongolia, China, between 2001 and 2013. *Exp Ther Med*. 2016;12(2):1220-1224. doi:10.3892/etm.2016.3393

[66] Jakob A, Whelan J, Kordecki M, *et al*. Kawasaki disease in Germany: a prospective, population-based study adjusted for underreporting. *Pediatr Infect Dis J*. 2016;35:129–34.

[67] Pinto FF, Laranjo S, Mota Carmo M, *et al*. Twelve years of Kawasaki disease in Portugal: epidemiology in hospitalized children. *Pediatr Infect Dis J*. 2017;36:364–8.

[68] Tacke CE, Breunis WB, Pereira RR, Breur *et al*. Five years of Kawasaki disease in the Netherlands: a national surveillance study. *Pediatr Infect Dis J*. 2014;33:793–7.

[69] Tulloh RMR, Mayon-White R, Harnden A, *et al*. Kawasaki disease: a prospective population survey in the UK and Ireland from 2013 to 2015. *Arch Dis Child*. 2019;104:640–6.

[70] Durongpisitkul K, Sangtawesin C, Khongphatthanayopthin A, *et al*. Epidemiologic study of Kawasaki disease and cases resistant to IVIG therapy in Thailand. *Asian Pac J Allergy Immunol*. 2006;24:27–32.

[71] Shoham AB, Haklai Z, Dor M, Bar-Meir M. Rheumatic fever and Kawasaki disease among children in Israel. *Harefuah*. 2014;153:709–12

[72] García Rodríguez F, Flores Pineda ÁJ, Villarreal Treviño AV, *et al*. Kawasaki disease at a pediatric hospital in Mexico. *Bol Med Hosp Infant Mex*. 2016;73:166–73.

[73] Sundel R ,Klein-Gitelman M, MPH Sheldon . Kawasaki disease: Epidemiology and etiology . www.uptodate

 Accessed : 10/7/202

https://www.uptodate.com/contents/kawasaki-disease-epidemiology-and-etiology/print

[74] Lu X, Zhang L, Du H, *et al*. Chinese Pediatric Novel Coronavirus Study Team. SARS-CoV-2 Infection in Children. *N Engl J Med*.2020;382:1663 5. doi:10.1056/NEJMc2005073. pmid:32187458

[75] Barry, John M. The site of origin of the 1918 influenza pandemic and its public health implications. *Journal of Translational Medicine*. 2004;2(1):3.

[76] Cheng KF, Leung PC. What happened in China during the 1918 influenza pandemic? *Int J Infect Dis*. 2007;11(4) 360-364. doi:10.1016/j.ijid.2006.

[77] Silva ME, Cherry JD, Wilton RJ, *et al*. Acute fever and petechial rash associated with influenza A virus infection. *Clin Infect Dis*. 1999;29:453–4.

[78] Shachor-Meyouhas Y, Kassis I. Petechial rash with pandemic influenza (H1N1) infection. *Pediatr Infect Dis J*. 2010;29(5):480. doi:10.1097/INF.0b013e3181d40ced

[79] Zhu S, Xia L, Yu S, Chen S, Zhang J. The burden and challenges of tuberculosis in China: findings from the Global Burden of Disease Study 2015 [published correction appears in *Sci Rep*. 2018 Jan 24;8(1):1746]. *Sci Rep*. 2017;7(1):14601. Published 2017 Nov 6. doi:10.1038/s41598-017-15024-1

[80] Gagnon A, Miller MS, Hallman SA, et al. Age-specific mortality during the 1918 influenza pandemic: unravelling the mystery of high young adult mortality. *PLoS One*. 2013;8(8):e69586. .doi:10.1371/journal.pone.0069586

[81] Vikki Valentine (20 February 2006). "Origins of the 1918 Pandemic: The Case for France". National Public Radio. Accessed from NPR site in 13 July 2020.
https://www.npr.org/templates/story/story.php?storyId=5222069

[82] Connor S (8 January 2000). "Flu epidemic traced to Great War transit camp". *The Guardian*. UK. Accessed from The Guardian site in   16 july 2020.
https://www.theguardian.com/world/2018/sep/09/spanish-flu-pandemic-centenary-first-world-war

[83] Oxford JS. The so-called Great Spanish Influenza Pandemic of 1918 may have originated in France in 1916. *Philos Trans R Soc Lond B Biol Sci*. 2001;356(1416):1857-1859. doi:10.1098/rstb.2001.1012

[84] Oxford JS, Lambkin R, Sefton A, *et al* . A hypothesis: the conjunction of soldiers, gas, pigs, ducks, geese and horses in northern France during the Great War provided the conditions for the emergence of the "Spanish" influenza pandemic of 1918–1919. *Vaccine*. 2005;23:940–945. doi: 10.1016/j.vaccine.2004.06.035

[85] Price-Smith AT (2008). *Contagion and Chaos.* Cambridge, MA: MIT Press. *ISBN 978-0-262-66203-1.*

[86] Love AG. A brief summary of the viral statistics of the US Army during the World War. *Mil Surg* 1922; 51: 139–68.

[87] Morens DM, Taubenberger JK. A forgotten epidemic that changed medicine: measles in the US Army, 1917-18. *Lancet Infect Dis*. 2015;15(7):852-861. doi:10.1016/S1473-3099(15)00109-7

[88] Vaughan VC, Palmer GT. Communicable diseases in the National Guard and National Army of the United States during the six months from September 29, 1917, to March 29, 1918. J Lab Clin Med 1918; 3: 635–718.

[89] Greenway JC, Boettiger C, Colwell HS. Pneumonia and some of its complications at Camp Bowie. *Arch Intern Med* .1919; 24: 1–34.

[90] Callendar GR. Pathology of the acute respiratory diseases. I. In camps in the United States. In: Ireland MW, Callendar GR, Coupal JF, eds. *The Medical Department of the United States Army in the World War*. Volume XII. Pathology of the acute respiratory diseases, and of gas gangrene following war wounds. Washington DC: US Government Printing Office, 1929: 7–186.

[91] Cole R, MacCallum WG. Pneumonia at a base hospital. J Am Med Assoc 1918; 70: 1146–56.

[92] Fornell D.2020 .*Kawasaki-like Inflammatory Disease Affects Children With COVID-19*. Diagnostic and Interventional Cardiology .
https://www.dicardiology.com/article/kawasaki-inflammatory-disease-affects-children-covid-19
Accessed :1/7/2020

[93] Noymer A,The 1918 influenza pandemic hastened the decline of tuberculosis in the United States: An age, period, cohort analysis,*Vaccine*, 29, Supplement 2;2011: B38-B41,

[94] Japan International Cooperation Agency (March 2005). Infectious Diseases Control (Tuberculosis, Parasitic Disease, Immunization Programs) in *: Japan's Experiences in Public Health and Medical Systems* . p114

[95] Kim JH, Yim JJ. Achievements in and Challenges of Tuberculosis Control in South Korea. *Emerg Infect Dis*. 2015;21(11):1913-1920. doi:10.3201/eid2111.141894

[96] Sumi A, Kamo K, Ohtomo N, Mise K, *et al.* Time series analysis of incidence data of influenza in Japan. *J Epidemiol*. 2011;21(1):21-29. doi:10.2188/jea.je20090162

[97]Komadina N, McVernon J, Hall R, Leder K. A historical perspective of influenza A(H1N2) virus. *Emerg Infect Dis*. 2014;20(1):6-12. doi:10.3201/eid2001.121848

[98] CDC (1982). *International Notes Influenza – Worldwide.*MMWR .1982 ; 31(8): 107

https://www.cdc.gov/mmwr/preview/mmwrhtml/00000217.htm
Accessed :1/7/2020

[99] CDC. *Antigenic variation of recent influenza A(H1N1) viruses*. MMWR 1986;35:510-2

[100] Nakamura Y, Yashiro M, Uehara R, etal . Epidemiologic Features of Kawasaki Disease in Japan: Results of the 2009–2010 Nationwide Survey. *J Epidemio* 2012;22(3):216-21.doi: 10.2188/jea.je20110126. Epub 2012 Mar 10.

https://www.researchgate.net/publication/221975930_Epidemiologic_Features_of_Kawasaki_Disease_in_Japan_Results_of_the_2009-2010_Nationwide_Survey
 Accessed :Jul 04 2020.

[101] CDC 1983. Influenza surveillance report no. 93, August 1977-March 1979
https://stacks.cdc.gov/view/cdc/289

Accessed :1/7/2020

[102] CDC. Multiple Outbreaks of Kawasaki Syndrome -- United States.*MMWR* .1985 ;34(3):33-35.
https://www.cdc.gov/mmwr/preview/mmwrhtml/00000470.htm
Accessed :1/7/2020

[103] CDC. Current Trends Influenza -- United States, 1983-1984 Season . *MMWR*.1984 ;33(29):417-
https://www.cdc.gov/mmwr/preview/mmwrhtml/00000378.htm

accessed : 2/7/2020

[104]   The   world   bank.   *Incidence   of   tuberculosis   (per   100,000   people)*
https://data.worldbank.org/indicator/SH.TBS.INCD retrived17/7/202
Accessed :1/7/202

[105]Cho KS. Tuberculosis control in the Republic of Korea.*Epidemiol Health*. 2018;40:e2018036. doi:10.4178/epih.e2018036

[106]   Frazer J .Kawasaki disease origin traced to northeast China .*Nature International Weekly Journal of Science*. 19 May 2014

https://www.nature.com/news/kawasaki-disease-origin-traced-to-northeast-china-1.15252#:~:text=Kawasaki%20disease%20could%20be%20the,National%20Academy%20of%20Sciences1.
Accessed: 2/7/2020

[107] Ma XJ, Yu CY, Huang M, Chen SB, Epidemiologic features of Kawasaki disease in Shanghai from 2003 through 2007.Shanghai Kawasaki Research Group.

Chin Med J (Engl). 2010 Oct; 123(19):2629-34.

[108]Singh S, Vignesh P, Burgner D. The epidemiology of Kawasaki disease: a global update. *Arch Dis Child*. 2015 Nov; 100(11):1084-8.

[109] Kilbourne ED. Influenza-1979. The *American Journal of Medicine*. 1979; 66:371-372

[110] CDC. Influenza – Worldwide. *MMWR.* 1982; 31(36):494-
 https://www.cdc.gov/mmwr/preview/mmwrhtml/00001158.htm
accessed : 1/7/2020

111 Colditz GA, Berkey CS, Mosteller F, et al. The efficacy of Bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. 1995. In: *Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews* [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995-.

Available from: https://www.ncbi.nlm.nih.gov/books/NBK66429/

Accessed :10/7/2020

[112] European Centre for Disease Prevention and Control: *Vaccine Schedule*.
Available at: http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx.
Accessed 3April2015
[113] Berger S *.Infectious Diseases of Luxembourg* . 2020 edition p301.